Lifecore Biomedical Announces Special Stockholder Meeting
17. Januar 2025 17:24 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Electronic Chemicals CDMO & CRO Market Global Forecast to 2029: Rising Miniaturization Trend Spurs 6.8% CAGR for Electronic Chemicals Outsourcing
15. Januar 2025 05:50 ET
|
Research and Markets
Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Electronic Chemicals CDMO & CRO Market by Type, Scale, Application, End-Use & Region-Global Forecast to 2029" report has been added to ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
13. Januar 2025 09:00 ET
|
ERS Genomics
ERS Genomics (‘ERS’), the CRISPR licensing company, today announces the launch of its Express License platform.
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
07. Januar 2025 09:00 ET
|
Lifecore Biomedical, Inc.
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE)...
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
06. Januar 2025 16:05 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
02. Januar 2025 16:05 ET
|
Lifecore Biomedical, Inc.
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3...
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19. Dezember 2024 16:05 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
19. Dezember 2024 07:00 ET
|
Lifecore Biomedical, Inc.
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and...
RTI Surgical Transforms into Evergen, a Leading CDMO in Regenerative Medicine
17. Dezember 2024 08:00 ET
|
Evergen
ALACHUA, Fla., December 17, 2024 – RTI Surgical ("the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, today...
Global CMO/CDMO Market to Reach USD 38.87 Billion by 2032, Driven by Rising Demand for Outsourced Drug Manufacturing | Research by SNS Insider
12. Dezember 2024 08:00 ET
|
SNS Insider pvt ltd
Austin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CMO/CDMO Market Size Analysis: “According to SNS Insider, the CMO/CDMO Market reached USD 23.32 billion in 2023 and is anticipated to grow up to USD 38.87...